Arthrosi Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Arthrosi Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Arthrosi Therapeutics: 7 sponsored US clinical trials, 1 recruiting.
Arthrosi Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gout Chronic, with 3 trials.
Upper-quartile sponsor footprint
Arthrosi Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
NCT07116746
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
NCT06439602
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
NCT05253833
Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
NCT05119686
Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment
NCT04646889
Single-dose AME Study With [14C]AR882 in Healthy Male Subjects
NCT04508426
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Arthrosi Therapeutics pipeline
1 recruiting of 7 indexed (14% open); 4 completed (57%).
Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Gout Chronic (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Arthrosi Therapeutics: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Arthrosi Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Arthrosi Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of Arthrosi Therapeutics or any single study.
- 1 of Arthrosi Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Gout Chronic is the condition Arthrosi Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gout Chronic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Arthrosi Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.